Overview
Directors
Executive Management
Codes of Conduct
|
|
 |
|
Professor Bryan R.G. Williams, Ph.D.
Non-Executive Chairman |
| |
Professor Williams was appointed Chairman of the Board of Directors in November 2006. He has been one of the Company's directors since March 2006. Professor Williams has over 30 years of experience in basic and pre-clinical cancer research. Since January 2006, he has been the director of the Monash Institute of Medical Research in Melbourne, Australia. From 1991 to 2005, Professor Williams was Chairman of the Department of Cancer Biology, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, Ohio. From 1993 to 2005, he was Professor, Department of Genetics at Case Western Reserve University, Cleveland, Ohio. From 1998 to 2005, he was an Adjunct Professor in the Departments of Chemistry at Cleveland State University and Kent State University, also both in Ohio. Professor Williams holds a BSc. (Hons) (Microbiology) and Ph.D. (Microbiology) from the University of Otago, New Zealand. He is an Honorary Fellow of the Royal Society of New Zealand. |
.jpg) |
|
Leah R. Cann, MBA
Non-Executive Director |
| |
Ms. Cann has been a director of Marshall Edwards since March 2009. She is an independent research analyst in Newport, Rhode Island. Ms. Cann began her career as a research scientist with Memtec Corporation and moved to Wall Street in 1992, where she was a research analyst with CIBC Oppenheimer for nearly nine years. She was a heath care analyst for the Boston-based asset manager, Cadence Capital, and later the senior biotechnology analyst for Wachovia Securities. Twice recognized as an All-Star analyst by the Wall Street Journal, Ms. Cann is the founder of Leah Rush Cann Research and Consulting, LLC, a Newport, Rhode Island-based cancer research and consulting organization. She is also Founder and Chairman of the Board of Hope Funds for Cancer Research, and a member of the New York Academy of Sciences. Ms. Cann received a BA in Art History and Chemistry and an MBA from Stetson University. She was a post-baccalaureate at the College of William and Mary and a post-graduate at Columbia University. She has been a trustee and member of several committees of International House in New York City for more than 10 years. |
 |
|
Daniel P. Gold, Ph.D.
President & CEO |
| |
Dr. Gold was appointed President and Chief Executive Officer of Marshall Edwards in April 2010. He joined the Company with more than 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that raised more than $200 million to advance the company's lead oncology candidate through a pivotal Phase III clinical trial. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a B.A. in Biology from the University of California Los Angeles. |
 |
|
Philip A. Johnston
Non-Executive Director |
| |
Mr. Johnston has been a director since April 2001. He has more than 25 years of experience in the pharmaceutical industry. He has been a non-executive director of Novogen Limited, the Company's parent, since 1997 and chairman of Novogen since January 2001. Mr Johnston is the managing director of Qualcare Management Pty. Ltd. He has been a director of Glycotex, Inc., a subsidiary of Novogen, since September 2005. From June 1988 to September 1997, he was an executive director of Wellcome Australia Limited. He was previously a director of two subsidiary companies of GlaxoWellcome. He has had responsibility for production, distribution, quality assurance and consumer product development and has been directly involved in the establishment of strategic alliances and joint ventures. Mr. Johnston has completed a number of executive development programs including programs at the University of New South Wales and the London Business School. |
 |
|
Christine A. White, M.D.
Non-Executive Director |
| |
Dr. White was appointed as a director of Marshall Edwards in August 2010. She was with Biogen Idec from 1996 to 2005, most recently as Senior Vice President, Global Medical Affairs, where she played an integral role in the clinical development, regulatory affairs and commercialization of oncology drugs Rituxan® and Zevalin®. Previously, she served as the Director of Clinical Oncology Research at the Sidney Kimmel Cancer Center in San Diego, and in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, California, most recently as Chairman. Dr. White currently serves as a member of the board of directors of Arena Pharmaceuticals, a clinical-stage biopharmaceutical company, and Genoptix, a specialized laboratory services provider. She also served as a director of Pharmacyclics, a biopharmaceutical company, and Monogram Biosciences, a life sciences company, until its acquisition by LabCorp in August 2009. Dr. White earned her B.A. in Biology and her M.D. from the University of Chicago and is Board certified in both Internal Medicine and Medical Oncology. |
|
|
| Contact Details |
|
| |
Marshall Edwards, Inc.
11975 El Camino Real
Suite 101
San Diego, CA 92130
T: (858) 792-6300
email  |
